COMPOSITION FOR INHIBITING PRODUCTION OF IL-8 FROM ACTIVATED T CELL
|Posted date||Apr 25, 2019|
|International application number||2018JP020696|
|International publication number||WO 2018221562|
|Date of international filing||May 30, 2018|
|Date of international publication||Dec 6, 2018|
|Title||COMPOSITION FOR INHIBITING PRODUCTION OF IL-8 FROM ACTIVATED T CELL|
|Abstract||According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).|
|Outline of related art and contending technology||
T helper is responsible for the role of the immune cells, production of cytokines from the difference, Th1 (type 1 helper T cells), Th2 (type 2 helper T cells), Th17 (type 17 helper T cells) such as classifications.
Conventionally, the abnormal Th1/Th2 balance involved in the development of various immune-related disease is thought, for example, the balance of the deflection to the cell Th1, a chronic inflammatory disease is rheumatoid arthritis, organ-specific autoimmune diseases (e.g., multiple sclerosis, 1 diabetes, inflammatory bowel disease, glomerulonephritis, hepatitis, liver disorders, autoimmune hemolytic anemia, leukopenia, thrombocytopenia, demyelinating disease, Hashimoto's thyroiditis, pernicious anemia, psoriasis) or the like and thought to be involved, in addition, the balance of the deflection to the cells Th2, such as allergic diseases, systemic autoimmune diseases often thought to be involved. On the other hand, the cells Th17, exclusively by producing IL-17, autoimmune inflammatory involved in the progression of, in particular above, 1 type II diabetes, inflammatory bowel diseases, psoriasis, multiple sclerosis, rheumatoid arthritis and is, the suspected due to the deflection Th17 are considered to be strong (non-patent document 1).
Immune system is complicated and various factors involved, to which an immune-related disease, Th1 deflection, the deflection Th2, Th17 are involved in one of the deflection is, in many cases is still unknown, the inventors of the present invention, already, dendritic cells Th1/Th2/Th17 via the mechanism of differentiation, is largely responsible for the function of dopamine (DA) are respectively found (Patent Document 1). In this report, specifically, on the dendritic cells as dopamine D1 receptor, antagonist is allowed to act on, the synthesis of dopamine in dendritic cells and storage is suppressed, as a result, naive T cells or Th17 cells to Th2 cells is suppressed and the induction of differentiation, to facilitate the induction of differentiation of Th1 cells is shown. Further, a dopamine D2 receptors on dendritic cells to as, and acts on the antagonist, the synthesis of dopamine in dendritic cells, to facilitate storage, as a result, naive T cells to the cells Th1 is suppressed and the induction of differentiation, to facilitate the induction of differentiation into the cell Th2 is also shown.
On the other hand, the inventors of the present invention, as set forth in the hot water with the yellow (wogonin Chinese-based formulation) is possible to suppress the induction of differentiation of the cells Th17 and, when the cells Th17 Th1 cells of the berberine is possible to suppress the induction of differentiation are also reported (Non-Patent Document 2-4). However, these findings, a naive T cells from both cell Th to control the induction of differentiation and, activated already differentiated to control the function of Th is not.
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " COMPOSITION FOR INHIBITING PRODUCTION OF IL-8 FROM ACTIVATED T CELL "
- Saitama Medical University Medical Research Center, Division of Intellectual Property & Strategic Research Promotion
- URL: http://www.saitama-med.ac.jp/english/index.html
- Address: 1397-1,Yamane,Hidaka-city, Saitama, Japan , 350-1241
- Phone: 81-42-498-4948
- Fax: 81-42-984-4948